Christine Seidman Buys Merck Stock

Christine Seidman, an insider at Merck & Co., Inc. (NYSE:MRK), purchased 63 shares of the company on June 30, 2026. The shares were bought at an average price of $128.5 each, bringing the total value of the transaction to approximately $8,095.5.

Insider Buying and Selling at Merck & Co., Inc.

On June 30, 2026, Christine Seidman added 63 shares of Merck to her holdings at a price of $128.5 per share. This transaction was not part of a pre-planned trading program. Other insiders, including Mary Ellen Coe and Surendralal Karsanbhai, also bought shares on the same date, each purchasing 234 and 127 shares, respectively, at the same price. Earlier, on May 29, 2026, Kathy Warden and Paul Rothman acquired 1,853 shares each at $118.72 per share.

Other Institutional Activity in Merck & Co., Inc.

BlackRock, Inc. increased its holdings in Merck by 6,734,865 shares, reaching a total of 225,830,330 shares valued at approximately $27.17 billion, marking a 3.1% increase. Vanguard Capital Management LLC initiated a new position with 160,987,624 shares worth about $19.37 billion. State Street Corp reduced its stake by 714,495 shares to 119,325,673 shares, valued at $14.45 billion, a 0.6% decrease. Wellington Management Group LLP trimmed its holdings by 2,120,487 shares, ending with 84,314,971 shares valued at $10.14 billion, a 2.5% reduction.

Merck & Co., Inc. Stock Down 13.4%

Shares of NYSE:MRK traded near $128.5 on Wednesday. Merck & Co., Inc. has a market cap of $317.37 billion, a P/E ratio of 36.20, and a forward P/E of 13.42. The stock has a 52-week low of $76.66 and a high of $130.29. It has a 50-day moving average of $116.12 and a 200-day moving average of $106.56. The company's beta is 0.218, indicating lower volatility compared to the market.

Analysts Set New Price Targets

On June 30, 2026, B of A Securities and Scotiabank both maintained their buy ratings on Merck, with price targets set at $141 and $155, respectively. Earlier, on June 24, 2026, CICC initiated coverage with a buy rating and a $138 target. The consensus among 28 analysts is a buy rating with an average target price of $130.39.

About Merck & Co., Inc.

Merck & Co., Inc., headquartered in Rahway, New Jersey, is a global healthcare company. It provides a wide range of pharmaceuticals for human health, including well-known brands like Keytruda and Gardasil. The company also offers veterinary pharmaceuticals and health management solutions. With a workforce of 73,000 employees, Merck is led by CEO Robert M. Davis. The company has strategic collaborations with several firms to develop new therapies.

Bottom Line

Christine Seidman's recent purchase of Merck shares underscores insider interest in the company's stock. Merck, a major player in the healthcare sector, continues to attract institutional investment and maintain strong analyst support. Investors often look at insider buying as a positive sign, though it's essential to remember that these transactions might not reflect future performance.